Immunomic Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Immunomic Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH180942D
  • |
  • Pages: 31
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Immunomic Therapeutics Inc (ITI) is a biotechnology company that specializes in developing vaccines based on the patented lysosomal associated membrane protein or lamp technology. The company's pipeline product portfolio drugs for allergy vaccine therapy and oncology immunotherapy. It develops vaccine therapies by incorporating the genetic sequence for LAMP protein as part of the DNA vaccine. ITI's product development pipeline also focuses on the allergy product area for internal development including products for global cedar, juniper, cypress allergy, peanut allergy and flea allergy in dogs. The company's LAMP-vax technology vaccines encode the expression of a fusion protein that includes the therapeutic antigen and the LAMP targeting protein. ITI is headquartered in Rockville, Maryland, the US.

Immunomic Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details

Venture Financing

Immunomic Therapeutics Raises USD4.6 Million in Venture Financing

Immunomic Therapeutics Raises USD1 Million In Venture Financing

Immunomic Therapeutics Raises USD3 Million In Venture Financing

Immunomic Therapeutics Raises USD3 Million In Pre-Series B Financing Round

Immunomic Therapeutics Raises USD1.6 Million In Venture Financing

Immunomic Therapeutics Raises USD2.7 Million In Venture Financing

Immunomic Therapeutics Raises USD1.1 Million In Venture Financing

Immunomic Therapeutics Raises USD2 Million In Series A Financing

Partnerships

Immunomic Therapeutics Enters into Research Agreement with Duke University

Licensing Agreements

Immunomic Therapeutics Enters into Licensing Agreement with Trianni

Immunomic Therapeutics Enters into Licensing Agreement with Annias Immunotherapeutics

Astellas Pharma Enters into Licensing Agreement with Immunomic Therapeutics

Immunomic Therapeutics Enters into Licensing Agreement with Nature Technology

Equity Offering

Immunomic Therapeutics Raises USD7 Million in Private Placement of Series A Preferred Shares

Immunomic Therapeutics Inc-Key Competitors

Immunomic Therapeutics Inc-Key Employees

Immunomic Therapeutics Inc-Locations And Subsidiaries

Head Office

Recent Developments

Corporate Communications

Dec 13, 2017: Immunomic Therapeutics Welcomes Key Thought Leader in Immuno-Oncology, Dr. Drew Pardoll, to Its Scientific Advisory Board

Nov 29, 2017: Immunomic Therapeutics' Founder Appointed to Maryland Life Sciences Advisory Board

Jan 05, 2017: Immunomic Therapeutics' Scientific Advisory Board Expansion

Product News

07/31/2017: Immunomic Therapeutics Welcomes New Oncology Advisor

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

List of Figures

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

List of Tables

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Immunomic Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Immunomic Therapeutics Raises USD4.6 Million in Venture Financing

Immunomic Therapeutics Raises USD1 Million In Venture Financing

Immunomic Therapeutics Raises USD3 Million In Venture Financing

Immunomic Therapeutics Raises USD3 Million In Pre-Series B Financing Round

Immunomic Therapeutics Raises USD1.6 Million In Venture Financing

Immunomic Therapeutics Raises USD2.7 Million In Venture Financing

Immunomic Therapeutics Raises USD1.1 Million In Venture Financing

Immunomic Therapeutics Raises USD2 Million In Series A Financing

Immunomic Therapeutics Enters into Research Agreement with Duke University

Immunomic Therapeutics Enters into Licensing Agreement with Trianni

Immunomic Therapeutics Enters into Licensing Agreement with Annias Immunotherapeutics

Astellas Pharma Enters into Licensing Agreement with Immunomic Therapeutics

Immunomic Therapeutics Enters into Licensing Agreement with Nature Technology

Immunomic Therapeutics Raises USD7 Million in Private Placement of Series A Preferred Shares

Immunomic Therapeutics Inc, Key Competitors

Immunomic Therapeutics Inc, Key Employees

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16998
Site License
USD 500 INR 33995
Corporate User License
USD 750 INR 50993

NEWSLETTER BY CATEGORY




Testimonials

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com